SCHEMBL22802424

SCHEMBL22802424

CCc1ccc(OC)c(S(=O)(=O)Nc2noc3cc(Cn4cccn4)cc(OC)c23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ KAT6A Q92794 20/20 1.00
▸ KAT7 O95251 19/20 1.00
▸ KAT6B Q8WYB5 16/20 1.00
▸ KAT5 Q92993 16/20 1.00
▸ KAT8 Q9H7Z6 16/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22817322 0.93 KAT6A (1.00) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL22817329 0.91 KAT7 (1.00) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL22817446 0.91 KAT7 (1.00) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL31372020 0.91 KAT6A (0.83) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL30680835 0.91 KAT7 (0.83) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL22802508 0.91 KAT7 (0.83) KAT6AKAT7KAT6BKAT5KAT8
Prifetrastat SCHEMBL29490368 0.90 KAT7 (0.90) KAT6AKAT7KAT6BKAT5KAT8
Prifetrastat SCHEMBL22802427 0.90 KAT7 (0.90) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL31472954 0.90 KAT6A (0.88) KAT6AKAT7KAT6BKAT5KAT8
SCHEMBL31371607 0.90 KAT7 (0.82) KAT6AKAT7KAT6BKAT5KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 — — US disclosed
US-12545669-B2 Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2026-02-10 — — US disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 — — EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 — — US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 — — EP disclosed
CN-114364672-B Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2024-09-06 — — CN disclosed
EP-4299135-A2 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2024-01-03 — — EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 — — EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 — — EP disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 — — US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 — — US disclosed
US-11492346-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2022-11-08 — — US disclosed
US-20220251075-A1 Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2022-08-11 — — US disclosed
EP-3986890-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2022-04-27 — — EP disclosed
CN-114364672-A Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2022-04-15 — — CN disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 — — US disclosed
WO-2020254989-A1 CYCLOALKYL AND HETEROCYCLOALKYL BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR KAT6A 3700/4885KAT7 1841/4885KAT6B 2765/4885
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR KAT6A 3783/4885KAT7 1917/4885KAT6B 2859/4885
US-20220251075-A1 Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives BRIX1, CCNA1, RB1 KAT6A 3964/4885KAT7 1804/4885KAT6B 2525/4885
US-12545669-B2 Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives NHERF1, CBX8, BCL9 KAT6A 1456/4885KAT7 725/4885KAT6B 2032/4885
US-11492346-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR KAT6A 3700/4885KAT7 1841/4885KAT6B 2765/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 KAT6A 7/4885KAT7 3/4885KAT6B 16/4885
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR KAT6A 3700/4885KAT7 1841/4885KAT6B 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback